Close Menu

NEW YORK – Announcing a collaboration with the University of Maryland School of Medicine earlier this week, biotech startup Anixa Biosciences (formerly Anixa Diagnostics) now expects to commercially launch its prostate cancer confirmation assay by early 2020.  

The San Jose, California-based firm, which was founded in 2017, will offer the test as an intermediate step that patients with high PSA levels can use prior to undergoing invasive tumor biopsy surgery. 

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try 360Dx Premium now.

You may already have institutional access!

Check if I qualify.

Already a 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.
Sponsored by
LGC SeraCare Life Sciences

This webinar features a panel of industry stakeholders in cancer diagnostics, proficiency testing and clinical care who will discuss the promise and challenges of liquid biopsy technologies in disease diagnosis, monitoring, and patient care management.